EFFECTS OF RECOMBINANT HUMAN BRAIN NATRIURETIC PEPTIDE COMBINED WITH NICORANDIL ON CARDIAC FUNCTION, NT-PROBNP, LP-PLA2 AND OXIDATIVE STRESS INDICATORS IN PATIENTS WITH ISCHEMIC HEART FAILURE

Xin Li¹, Xiaozeng Li¹, Xiangling Qiao¹, Qingqing Zhang¹, Liping Qi^{2, *}

¹Department of Cardiology Intensive Care Unit, Xingtai Third Hospital, Xingtai, 054099, China - ²Department of Office, Xingtai Third Hospital, Xingtai, 054000, China

Objective: To analyze the effects of recombinant human brain natriuretic peptide combined with nicorandil on cardiac function, N-terminal pro-B-type natriuretic peptide (NT-proBNP), lipoprotein-related phospholipase A2 (Lp- PLA2) and oxidative stress indicators. 

Methods: Eighty-six patients with ischemic heart failure who visited the outpatient clinic or were hospitalized from June 2018 to March 2020 were randomly divided into a conventional control group and a treatment group, with 43 patients in each group. The control group was given recombinant human brain natriuretic peptide, and the treatment group was given nicorandil on the basis of the control group. The clinical efficacy and cardiac function after treatment (left ventricular end systolic volume [LVESV], left ventricular end diastolic diameter [LVEDD], and left ventricular ejection fraction [LVEF]) and levels of NT-proBNP, Lp-PLA2 and oxidative stress changes as well as adverse reactions of patients in the two groups were compared. 

Results: After treatment, the total effective rate of the treatment group was 93.02%, which was significantly higher than the rate of the control group (P<0.05). The levels of LVESV, LVEDD, NT-proBNP, Lp-PLA2 and MDA in the two groups were significantly decreased after treatment compared to levels before treatment. Additionally, the levels of LVEF and SOD were significantly increased after treatment compared to before treatment, and the improvement in the treatment group was significantly better than that in the control group (P<0.05). The incidence rate of adverse reactions in the treatment group and the control group were 13.95% and 23.26%, respectively, a difference that was statistically significant (P<0.05). 

Conclusion: Recombinant human brain natriuretic peptide combined with nicorandil demonstrates good efficacy in treating ischemic heart failure. This treatment can effectively improve the patient's heart function, regulate and reduce the levels of NT-proBNP and Lp-PLA2, and improve oxidative stress indicators.